NDATOPICALCREAM
Approved
Feb 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
FUNGIZONE (amphotericin b) by Bristol Myers Squibb is mechanism of action amphotericin b, the active ingredient of amphotericin b liposome for injection, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. First approved in 1966.
Drug data last refreshed 4h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUNGIZONE is a topical cream formulation of amphotericin B, a polyene antifungal agent approved since 1966. It treats various fungal infections including candidiasis, aspergillosis, and other mycoses by binding to fungal cell membrane ergosterol and disrupting cell permeability. The drug works through a well-established mechanism that has made it a foundational antifungal therapy.
LOE Approaching
As an established product approaching loss of exclusivity, FUNGIZONE represents a mature, stable portfolio asset with likely reduced team investment and focus on cost management rather than growth initiatives.
Mechanism of Action
Mechanism of Action Amphotericin B, the active ingredient of amphotericin B liposome for injection, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. It forms transmembrane channels leading to alterations in cell permeability through which monovalent…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Started Jul 2026
428 enrolled
Talaromycosis
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
Started May 2026
18 enrolled
Chronic Pulmonary Aspergillosis
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
Started Sep 2025
38 enrolled
Fungal Disease
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Started May 2025
42 enrolled
Invasive Fungal InfectionsNeutropenic FeverVisceral Leishmaniasis
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
Started Jan 2025
279 enrolled
Disseminated Histoplasma Capsulatum InfectionAIDS and InfectionsImmunosuppression+1 more
Worked on FUNGIZONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.